Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2010

Open Access 01-12-2010 | Primary research

CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation

Authors: Xueyan Yu, Junling Si, Yingjie Zhang, James W DeWille

Published in: Cancer Cell International | Issue 1/2010

Login to get access

Abstract

Background

CCAAT/enhancer binding protein-delta (C/EBP-delta) is a member of the highly conserved C/EBP family of basic region leucine zipper transcription factors. C/EBP family members regulate cell growth and differentiation and "loss of function" alterations in C/EBPs have been reported in a variety of human cancers. C/EBP-delta gene expression is upregulated by G0 growth arrest, IL-6 family cytokines and endotoxin treatments. C/EBP-delta exhibits properties of a tumor suppressor gene, including reduced expression and promoter methylation-induced silencing in transformed cell lines and primary tumors. In addition, C/EBP-delta gene expression is repressed by c-Myc, an oncogene that is over-expressed in a wide range of human cancers. "ChIP-chip" studies demonstrated that C/EBP-delta functions as a transcriptional activator of target genes that function in intracellular signal transduction, transcription, DNA binding/repair, cell cycle control, cell adhesion, and apoptosis. Despite progress in determining the biochemical functions of C/EBP-delta, the specific cellular defects that are induced by C/EBP-delta "loss of function" alterations are poorly understood. This study investigated the impact of C/EBP-delta "loss of function" alterations on growth arrest, migration/invasion and differentiation in nontransformed mouse mammary epithelial cells (MECs) and primary mouse embryo fibroblasts (MEFs).

Results

C/EBP-delta siRNA transfected MECs exhibited ~90% reduction in C/EBP-delta mRNA and protein levels. C/EBP-delta siRNA treatment resulted in defective growth arrest as demonstrated by persistently elevated BrdU labeling, 3H-thymidine incorporation and cyclin D1 levels in response to growth arrest treatments. C/EBP-delta siRNA treatment also resulted in increased migration/invasion and defective differentiation. C/EBP-delta knockout MEFs exhibited defective growth arrest and increased proliferation/migration. Re-introduction of C/EBP-delta expression restored the growth arrest response of C/EBP-delta knockout MEFs. Finally, deletion of the C/EBP-delta DNA binding domain or the C/EBP-delta bZIP domain resulted in the loss of C/EBP-delta growth inhibition in clonogenic assays.

Conclusions

This study demonstrates that C/EBP-delta functions in the regulation of critical cell fate determining programs such as growth arrest, migration, and differentiation. These results support the tumor suppressor function of C/EBP-delta and identify potential mechanisms in which "loss of function" alterations in C/EBP-delta could promote cell transformation and tumorigenesis.
Appendix
Available only for authorised users
Literature
1.
2.
Johnson PF: Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci. 2005, 118 (Pt 12): 2545-2555. 10.1242/jcs.02459.CrossRefPubMed
3.
Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M: Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol. 2002, 22 (18): 6321-6335. 10.1128/MCB.22.18.6321-6335.2002.PubMedCentralCrossRefPubMed
4.
Nerlov C: The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007, 17 (7): 318-324. 10.1016/j.tcb.2007.07.004.CrossRefPubMed
5.
O'Rourke J, Yuan R, DeWille J: CCAAT/enhancer-binding protein-delta (C/EBP-delta) is induced in growth-arrested mouse mammary epithelial cells. J Biol Chem. 1997, 272 (10): 6291-6296.CrossRefPubMed
6.
O'Rourke JP, Newbound GC, Hutt JA, DeWille J: CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis. J Biol Chem. 1999, 274 (23): 16582-16589.CrossRefPubMed
7.
O'Rourke JP, Hutt JA, DeWille J: Transcriptional regulation of C/EBPdelta in G(0) growth-arrested mouse mammary epithelial cells. Biochem Biophys Res Commun. 1999, 262 (3): 696-701.CrossRefPubMed
8.
Sivko GS, DeWille JW: CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines. J Cell Biochem. 2004, 93 (4): 830-843. 10.1002/jcb.20223.CrossRefPubMed
9.
Sanford DC, DeWille JW: C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate. 2005, 63 (2): 143-154. 10.1002/pros.20159.CrossRefPubMed
10.
Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP: C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene. 2005, 24 (9): 1589-1597. 10.1038/sj.onc.1208393.CrossRefPubMed
11.
Agrawal S, Hofmann WK, Tidow N, Ehrich M, van den Boom D, Koschmieder S, Berdel WE, Serve H, Muller-Tidow C: The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood. 2007, 109 (9): 3895-3905. 10.1182/blood-2006-08-040147.CrossRefPubMed
12.
Gigliotti AP, Johnson PF, Sterneck E, DeWille JW: Nulliparous CCAAT/enhancer binding proteindelta (C/EBPdelta) knockout mice exhibit mammary gland ductal hyperlasia. Exp Biol Med (Maywood). 2003, 228 (3): 278-285.
13.
Tang D, Sivko GS, Dewille JW: Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors. Breast Cancer Res Treat. 2005, 1-10.
14.
Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ: Molecular markers in ductal carcinoma in situ of the breast. MolCancer Res. 2003, 1 (5): 362-375.
15.
Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins G, Polyak K: A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001, 61 (15): 5697-5702.PubMed
16.
Kuramoto T, Morimura K, Yamashita S, Okochi E, Watanabe N, Ohta T, Ohki M, Fukushima S, Sugimura T, Ushijima T: Etiology-specific gene expression profiles in rat mammary carcinomas. Cancer Res. 2002, 62 (13): 3592-3597.PubMed
17.
Dearth LR, Hutt J, Sattler A, Gigliotti A, DeWille J: Expression and function of CCAAT/enhancer binding proteinbeta (C/EBPbeta) LAP and LIP isoforms in mouse mammary gland, tumors and cultured mammary epithelial cells. J Cell Biochem. 2001, 82 (3): 357-370. 10.1002/jcb.1167.CrossRefPubMed
18.
Strathdee G, Brown R: Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev Mol Med. 2002, 4 (4): 1-17. 10.1017/S1462399402004222.CrossRefPubMed
19.
Borrelli S, Testoni B, Callari M, Alotto D, Castagnoli C, Romano RA, Sinha S, Vigano AM, Mantovani R: Reciprocal regulation of p63 by C/EBP delta in human keratinocytes. BMC Mol Biol. 2007, 8: 85-10.1186/1471-2199-8-85.PubMedCentralCrossRefPubMed
20.
Lane MD, Tang QQ, Jiang MS: Role of the CCAAT enhancer binding proteins (C/EBPs) in adipocyte differentiation. BiochemBiophysResCommun. 1999, 266 (3): 677-683.
21.
Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA. 1997, 94 (8): 3801-3804. 10.1073/pnas.94.8.3801.PubMedCentralCrossRefPubMed
22.
Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, Taylor LR, Wilson DR, Darlington GJ: Impaired energy homeostasis in C/EBP alpha knockout mice. Science. 1995, 269 (5227): 1108-1112. 10.1126/science.7652557.CrossRefPubMed
23.
Ishii Y, Kasukabe T, Honma Y: Induction of CCAAT/enhancer binding protein-delta by cytokinins, but not by retinoic acid, during granulocytic differentiation of human myeloid leukaemia cells. Br J Haematol. 2005, 128 (4): 540-547. 10.1111/j.1365-2141.2004.05326.x.CrossRefPubMed
24.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
25.
Hutt JA, O'Rourke JP, DeWille J: Signal transducer and activator of transcription 3 activates CCAAT enhancer-binding protein delta gene transcription in G0 growth-arrested mouse mammary epithelial cells and in involuting mouse mammary gland. J Biol Chem. 2000, 275 (37): 29123-29131. 10.1074/jbc.M004476200.CrossRefPubMed
26.
Cantwell CA, Sterneck E, Johnson PF: Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol. 1998, 18 (4): 2108-2117.PubMedCentralCrossRefPubMed
27.
Sivko GS, Sanford DC, Dearth LD, Tang D, DeWille JW: CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: II. Analysis of activating signal transduction pathways, transcriptional, post-transcriptional, and post-translational control. J Cell Biochem. 2004, 93 (4): 844-856. 10.1002/jcb.20224.CrossRefPubMed
28.
Grant SL, Douglas AM, Goss GA, Begley CG: Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cells. Growth Factors. 2001, 19 (3): 153-162. 10.3109/08977190109001083.CrossRefPubMed
29.
Hutt JA, DeWille JW: Oncostatin M induces growth arrest of mammary epithelium via a CCAAT/enhancer-binding protein delta-dependent pathway. Mol Cancer Ther. 2002, 1 (8): 601-610.PubMed
30.
Vultur A, Cao J, Arulanandam R, Turkson J, Jove R, Greer P, Craig A, Elliott B, Raptis L: Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene. 2004, 23 (15): 2600-2616. 10.1038/sj.onc.1207378.CrossRefPubMed
31.
Minami M, Inoue M, Wei S, Takeda K, Matsumoto M, Kishimoto T, Akira S: STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci USA. 1996, 93 (9): 3963-3966. 10.1073/pnas.93.9.3963.PubMedCentralCrossRefPubMed
32.
Spiotto MT, Chung TD: STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate. 2000, 42 (2): 88-98. 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P.CrossRefPubMed
33.
Zhang Y, Liu T, Yan P, Huang T, Dewille J: Identification and characterization of CCAAT/Enhancer Binding proteindelta (C/EBPdelta) target genes in G0 growth arrested mammary epithelial cells. BMC Mol Biol. 2008, 9 (1): 83-10.1186/1471-2199-9-83.PubMedCentralCrossRefPubMed
34.
Liang CC, Park AY, Guan JL: In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007, 2 (2): 329-333. 10.1038/nprot.2007.30.CrossRefPubMed
35.
Jang AC, Starz-Gaiano M, Montell DJ: Modeling migration and metastasis in Drosophila. J Mammary Gland Biol Neoplasia. 2007, 12 (2-3): 103-114. 10.1007/s10911-007-9042-8.CrossRefPubMed
36.
Simpson KJ, Selfors LM, Bui J, Reynolds A, Leake D, Khvorova A, Brugge JS: Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol. 2008, 10 (9): 1027-1038. 10.1038/ncb1762.CrossRefPubMed
37.
Cao Z, Umek RM, McKnight SL: Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 1991, 5 (9): 1538-1552. 10.1101/gad.5.9.1538.CrossRefPubMed
38.
vom Brocke J, Schmeiser HH, Reinbold M, Hollstein M: MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis. 2006, 27 (11): 2141-2147. 10.1093/carcin/bgl101.CrossRefPubMed
39.
Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H, Koeffler HP: CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res. 2005, 65 (11): 4762-4768. 10.1158/0008-5472.CAN-03-3619.CrossRefPubMed
40.
Ray A, Ray BK: Serum amyloid A gene expression under acute-phase conditions involves participation of inducible C/EBP-beta and C/EBP-delta and their activation by phosphorylation. MolCell Biol. 1994, 14 (6): 4324-4332.
41.
Silva FP, Swagemakers SM, Erpelinck-Verschueren C, Wouters BJ, Delwel R, Vrieling H, van der Spek P, Valk PJ, Giphart-Gassler M: Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood. 2009, 114 (14): 3001-3007. 10.1182/blood-2009-03-211334.CrossRefPubMed
42.
Litvak V, Ramsey SA, Rust AG, Zak DE, Kennedy KA, Lampano AE, Nykter M, Shmulevich I, Aderem A: Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat Immunol. 2009, 10 (4): 437-443. 10.1038/ni.1721.PubMedCentralCrossRefPubMed
43.
Zhou S, Si J, Liu T, DeWille JW: PIASy represses CCAAT/enhancer-binding protein delta (C/EBPdelta) transcriptional activity by sequestering C/EBPdelta to the nuclear periphery. J Biol Chem. 2008, 283 (29): 20137-20148. 10.1074/jbc.M801307200.PubMedCentralCrossRefPubMed
44.
Zhou S, Dewille JW: Proteasome-mediated CCAAT/enhancer-binding protein delta (C/EBPdelta) degradation is ubiquitin-independent. Biochem J. 2007, 405 (2): 341-349. 10.1042/BJ20061873.PubMedCentralCrossRefPubMed
Metadata
Title
CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation
Authors
Xueyan Yu
Junling Si
Yingjie Zhang
James W DeWille
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2010
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-10-48

Other articles of this Issue 1/2010

Cancer Cell International 1/2010 Go to the issue

Editorial

Reflections on the responsible conduct of cancer research

Primary research

A natural compound from Hydnophytum formicarium induces apoptosis of MCF-7 cells via up-regulation of Bax

Hypothesis

From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer

Primary research

Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma

Primary research

Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon

Primary research

Bradykinin increases resensitization of purinergic receptor signaling in glioma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits